Human RCT Evidence is a recurring topic in our peptide coverage. This hub collects every article tagged Human RCT Evidence, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on carbetocin — the long-acting, heat-stable oxytocin analog. Grade A evidence for preventing postpartum hemorrhage, a failed Prader-Willi program, and a 2026 legal status that is not FDA-approved.
A clinical monograph on setmelanotide (Imcivree) — the MC4R-agonist octapeptide approved for rare genetic and hypothalamic obesity. Grade A human evidence in narrow indications, not a general weight-loss drug.
A clinical monograph on MK-677 (ibutamoren) — the oral, non-peptide ghrelin-receptor agonist that reliably raises GH and IGF-1, yet failed its clinical disease endpoints and carries a congestive-heart-failure safety signal.
A clinical monograph on Melanotan I — INN afamelanotide, marketed as SCENESSE — the only FDA-approved melanocortin agonist, with Grade-A EPP photoprotection data and a separate unapproved gray-market tanning identity.
A clinical monograph on mazdutide (IBI362 / LY3305677) — the first GLP-1/glucagon dual receptor agonist, backed by completed Phase 3 RCTs for obesity and type 2 diabetes, approved in China but investigational in the US.
A clinical monograph on lixisenatide (Adlyxin/Lyxumia) — the short-acting, exendin-4-derived GLP-1 receptor agonist for type 2 diabetes, with a large RCT base, proven cardiovascular safety, and an emerging Parkinson's signal.
A clinical monograph on liraglutide — the once-daily GLP-1 receptor agonist sold as Victoza and Saxenda. Grade A human RCT evidence for glycemic control, weight loss, and reduced cardiovascular death.
A clinical monograph on exenatide — the first-in-class GLP-1 receptor agonist (synthetic exendin-4) — with a focus on its Grade A pediatric type 2 diabetes evidence, mechanism, dosing from the literature, safety, and 2026 regulatory status.
A clinical monograph on CagriSema — Novo Nordisk's investigational once-weekly cagrilintide + semaglutide combination. Grade A Phase 3 RCT data, ~20-23% weight loss, and a 2026 legal status that is still investigational worldwide.
A clinical monograph on larazotide acetate (AT-1001) — the gut tight-junction regulator developed for celiac disease. Real Phase 2 symptom data, a failed Phase 3, and an unapproved 2026 legal status.
A clinical monograph on insulin — the prototype FDA-approved therapeutic peptide. Grade-A human evidence in diabetes, a tyrosine-kinase mechanism, and a stark warning on lethal non-medical 'anabolic' misuse.
A clinical monograph on the injectable FSH and LH analogs of reproductive medicine — Grade A, FDA-approved biologics validated by large RCTs and a Cochrane meta-analysis of ~9,600 couples, with OHSS and multiple gestation as the headline risks.
A clinical monograph on human chorionic gonadotropin (hCG) — the FDA-approved LH-mimetic hormone used to trigger ovulation and preserve intratesticular testosterone, with the 'hCG diet' debunked and illegal.
A clinical monograph on glycyl-L-glutamine (Gly-Gln) — the stable glutamine-carrier dipeptide of parenteral nutrition that is also the endogenous β-endorphin-(30–31) neuropeptide. Real human-trial evidence for IV glutamine delivery; cardiometabolic claims are preclinical only.
A clinical monograph on glucagon — the 29-amino-acid pancreatic counter-regulatory hormone. FDA-approved since 1960 for severe-hypoglycemia rescue, graded A on decades of human RCTs, and now the glucagon-receptor arm of next-generation metabolic agonists.
A clinical monograph on teduglutide — the GLP-2 receptor agonist FDA-approved for short bowel syndrome with intestinal failure. Grade A RCT evidence for SBS-IF, a mandated neoplasia-surveillance burden, and unproven 'leaky-gut' hype.
A clinical monograph on dulaglutide (Trulicity) — the once-weekly GLP-1-Fc fusion biologic with Grade A human RCT evidence for glycemic control and a 12% cardiovascular event reduction.
A clinical monograph on CJC-1295 with DAC — the albumin-tethered, long-acting GHRH analog. Small Phase 1 RCTs prove it raises GH and IGF-1 for days (Grade B), but no clinical-outcome trial exists, and it is unapproved and banned in sport.
A clinical monograph on Cerebrolysin — the porcine-brain-derived neuropeptide mixture studied for stroke, TBI and dementia. A large but deeply contested human-RCT base, no FDA approval, and an unresolved safety signal.
A clinical monograph on carnosine — the endogenous β-alanyl-L-histidine dipeptide. Strong human evidence for β-alanine-driven exercise capacity and modest glycemic control, undercut by a rapid-hydrolysis pharmacokinetic problem.
Human RCT Evidence is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Human RCT Evidence, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.